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SERUM INTERFERON LEVELS IN PATIENTS WITH 
SYSTEMIC LUPUS ERYTHEMATOSUS 
STEVEN R.  YTTERBERG and THOMAS J .  SCHNITZER 
Levels of interferon (IFN) were measured in 81 
serum samples from 23 patients with systemic lupus 
erythematosus (SLE) by a plaque-reduction method and 
correlated retrospectively with clinical records of dis- 
ease activity, anti-DNA binding, and serum complement 
measurements. IFN titers were found to correlate with 
both clinical disease activity and anti-DNA binding, but 
no relation was found to serum complement. Most 
(76.6%, 31 of 41) serum samples obtained during peri- 
ods of active disease contained measureable amounts of 
IFN, but only 9.1% (2 of 22) of results of tests on 
samples obtained during periods of disease quiescence 
were positive (P < 0.005). Of samples with clearly 
elevated anti-DNA binding (> 40%), 69.7% (23 of 33) 
had positive results for IFN, but 57.1% (8 of 14) had 
negative results when the anti-DNA binding was normal 
(< 20%) (P < 0.005). Measurement of serum IFN titers 
in patients with SLE, therefore, provides another sero- 
logic marker of disease activity. Contrary to the findings 
of previous studies, the IFN found in the present study 
was characterized as IFN-a, or Type I JFN, on the basis 
of acid stability and neutralization by antibody to IFN- 
a. Of interest are the questions raised about the origin of 
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IFN in the sera of patients with SLE and what role IFN 
might have in the pathogenesis of the autoimmune 
disease in view of the many documented immunomodu- 
lating effects of IFN. 
Interferon (IFN) was originally described in 
1957 as a glycoprotein, produced by cells infected by 
virus and able to exert an antiviral effect on other cells 
(1). This substance has come to be known as Type I 
IFN, and has been recognized to be induced by 
pharrnacologic agents and bacterial lipopolysaccharide 
in addition to viral infection (2). A second, closely 
related antiviral substance was subsequently discov- 
ered to be produced by lymphocytes in response to 
stimulation by nonspecific mitogens (3). This material, 
Type I1 IFN, can also be produced upon stimulation of 
sensitized lymphocytes by specific antigens or anti- 
gen-antibody complexes (4). Type I IFN has recently 
been subclassified as IFN-a if produced by leukocytes 
or IFN-P if produced by fibroblasts. Type 11 IFN is 
now termed IFN-y (5). 
In addition to antiviral effects, immunoregula- 
tory effects have been described for both types of IFN 
(4,6). In relation to antibody formation, high doses of 
IFN have been shown to be suppressive, but low 
doses enhance antibody production (7-9). Other ef- 
fects of IFN on elements of the immune system 
include: inhibition of memory cell formation (10); 
inhibition of delayed-type hypersensitivity ( 1  I )  and the 
graft-versus-host reaction (12); prolongation of allo- 
graft survival (13); and enhancement of natural killer 
(NK) cell activity (14-17) and antibody-dependent 
cell-mediated cytotoxicity (ADCC) ( 16,17). Interferon 
has also been shown to increase the expression of cell 
surface histocompatibility antigens ( 18) and to en- 
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hance the expression of receptors for the Fc fragment 
of IgG on T cell surfaces (19). Recently, other investi- 
gators have shown IFN to be  produced by mitogen- 
stimulated suppressor T cells, and have postulated 
that IFN mediates the suppressor activity of these 
cells (20). Thus ,  considerable evidence exists that IFN 
is actively involved in the immune system, since i t  is 
produced by antigenic stimulation and is capable of 
modulating diverse immune responses. T h e  specific 
physiologic role(s) IFN has in the control of the 
immune response is. however, unknown. 
T h e  observation of the close involvement of 
IFN with the immune system prompted this investiga- 
tion of IFN levels in the sera of patients with systemic 
lupus erythematosus (SLE), a disease characterized 
by alterations in the immune system. In similar investi- 
gations by two other groups, authors have docu- 
mented elevated levels of IFN in sera of patients with 
a range of rheumatic disorders, including SLE (21-23). 
In only one study, however, could a correlation be- 
tween IFN levels and disease activity in patients with 
SLE be demonstrated (21.22). In this present investi- 
gation, w e  have analyzed the correlation between 
serum IFN and several parameters of disease activity, 
including antibodies to  DNA and complement levels, 
and  have begun to characterize the type of IFN 
present in SLE serum. 
MATERIALS AND METHODS 
Patient selection and serum preservation. All patients 
included in this study were treated at the Arthritis Clinic of 
the University of Michigan Medical Center and met at least 4 
of the preliminary criteria of the American Rheumatism 
Association for the classification of SLE (24). An effort was 
made to locate patients with active SLE. Patient charts were 
reviewed to determine clinical disease activity and other 
laboratory data (the reviewer of the charts had no knowledge 
of the IFN titers). 
Activity was classified as grade 0 if there was no 
evidence of active disease noted in the chart, or grade I if i t  
could not be determined with assurance by either rhe initial 
examiner or chart reviewer that active disease was present. 
Patients with active disease were subclassified as having 
mild disease (grade 2) if one organ system showed evidence 
of activity (stable renal disease was not considered a sign of 
activity). Patients were classified as having severe disease 
(grade 4) if they had at least two organ systems involved, had 
been admitted to the hospital for more intensive therapy, or 
had had their prednisone dose significantly increased. Pa- 
tients who were classified as having moderate disease (grade 
3) had disease severity rated between the previous grade 2 
and grade 4 groups. Although this is not a quantitative scale 
of disease activity, it was devised to account for the fact that 
it is possible on chart review to differentiate between levels 
of active disease in patients with SLE. Control sera from 5 
patients with osteoarthritis and 6 healthy volunteers were 
also examined. Serum specimens were stored from the time 
of collection until assay at -70°C. 
Interferon assay. A microtiter plaque-reduction assay 
for interferon was used that is based on the ability of IFN to 
cause a linear, dose-dependent cellular resistance to viral 
infection (25).  Serum dilutions were made with Dulbecco’s 
modification of Eagle’s minimum essential medium (DMEM) 
supplemented with 2% newborn calf serum (NCS). Human 
amnion (WISH) cells were grown in microtiter plates as 
targets for the virus. Diluted serum, 0.1 ml. was added in 
triplicate to the cell monolayers and incubated overnight at 
37°C in 5% COz. The medium was then removed, and the 
cells were washed 3 times with DMEM-2% NCS. Between 
50 and 75 plaque-forming units of vesicular stomatitis virus- 
Indiana serotype (VSV) were added per well and allowed to 
adsorb for 1 hour at 37°C; 0. I ml of 2% methylcellulose was 
then added, and the cells were incubated at 37°C in 5% CO? 
for 48 hours. The cells were fixed with formalin. stained with 
Giemsa, and examined under a dissecting microscope for 
plaques. The IFN activity, in unitslml. was defined as the 
reciprocal of the highest dilution of serum able to reduce the 
number of plaques at least 50% as compared to controls. 
Controls contained no sera, 2% NCS. or known amounts of 
standard IFN. When titered by this assay system, 10’ units 
of NIH reference human leukocyte IFN #G-023-901-527 
yielded results between 3.2 x lo4 and 6.4 x lo4 units ( n  = 
20). 
Demonstration of the antiviral activity to be interfer- 
on. To demonstrate species specificity, samples were as- 
sayed on mouse L cell monolayers in addition to WISH 
monolayers by the technique outlined above for WISH cells. 
Further evidence that the observed antiviral activity was due 
to IFN and not to nonspecific antiviral activity was obtained 
by using neutralization assays with rabbit antibody to human 
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Figure 1. Relationship of IFN levels and disease activity. Disease 
activity was determined by chart review and classified as absent 
activity (O), possible or indeterminate activity ( I ) ,  and definitely 
active disease. subclassified as mild (2 ) .  moderate (3) .  or severe (4)  
on the basis of the clinical description and physician action ( P  < 
0.005. chi square; r = 0.62, P < 0.01). 
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IFN-a obtained from the Antiviral Substances Program of 
the National Institute of Allergy and Infectious Diseases. 
This antibody was raised toward Sendai virus-induced hu- 
man leukocyte IFN-a and was purified by immunoabsorp- 
tion. It has a titer of 1 : 10,000 toward human IFN-a with a 
titer of only 1 :240 toward human foreskin IFN-P. The 
antibody has also been shown to contain titers of less than 
1 : 24 toward antigens from human leukocyte extracts, gam- 
maglobulin, and albumin. Briefly, 0.1 ml of various antibody 
dilutions in DMEM-2% NCS were incubated with 0.1 ml of 
positive serum samples at 1 dilution below the end-point titer 
for 1 hour at 37°C. Samples were then handled according to 
the standard IFN assay as outlined above. Acid stability was 
examined by dialyzing aliquots of positive serum samples 
overnight at 4°C against baths of phosphate-buffered saline 
titrated to pH 2 or pH 7 with HCI. The samples were then 
redialyzed against pH 7 buffer and assayed with the standard 
IFN assay (21). 
Statistical methods. Chi square analysis was used to 
test the significance of positive IFN titers versus disease 
activity, anti-DNA binding, and serum complement with 4, 
4, and 1 degrees of freedom, respectively. Additional analy- 
sis of the data to compare actual IFN titers and levels of 
disease activity was done with a linear correlation coefficient 
analysis, and changes of levels in individual patients were 
compared by means of the sign test. 
RESULTS 
Eighty-one serum samples were analyzed from 
23 patients with SLE (1-9 samples per patient). Posi- 
tive samples were defined as those containing 2 8 
U/ml of IFN. Overall, 70% (16/23) of patients with 
SLE had at least 1 positive IFN titer, and 49% (40/81) 
of the serum samples analyzed had positive results. 
Sera from 5 patients with osteoarthritis and 6 healthy 
volunteers had negative results for IFN. When the 
data were analyzed in relation to disease activity 
(Figure I),  75.6% (31/41) of samples collected from 
patients during periods of definite disease activity had 
positive results, whereas only 9.1% (2/22) of samples 
obtained during periods of disease quiescence had 
positive results. In 18 instances, the presence or 
absence of disease could not be determined with 
certainty by chart review; 38.9% (7/18) of these sam- 
ples had positive IFN test results. These data are 
statistically significant ( P  < 0.005, chi-square; r = 
0.62, P < 0.01). The relationship of IFN titers to 
disease activity of individual patients was also ana- 
lyzed. Comparing the IFN titers from the periods with 
the greatest and least disease activity within the same 
patient, the IFN titers varied directly with disease 
activity in 10 patients, were unchanged in 4 patients, 
and varied inversely with disease activity in no pa- 
tients ( P  < 0.05, sign test). 
Table 1. 
activities* 
Relationship of serum interferon and anti-DNA binding 
Interferon 
Negative Pcsitive Anti-DNA binding - 
(%I No. % No. % Total 
0-20 8 57.1 6 42.9 14 
20-40 22 68.8 10 31.2 32 
40-60 6 50.0 6 50.0 12 
60-80 4 33 .3  8 66.7 12 
80-100 0 0.0 9 100.0 9 
* P < 0.005, chi square. 
The relationship of the presence of positive IFN 
titers and anti-DNA binding activities of individual 
serum samples from all patients studied is shown in 
Table 1. Of patients with normal anti-DNA binding 
activities (defined as < 20%), 57.1% (8/14) had nega- 
tive IFN titers. However, 69.7% (23/33) of patients 
with clearly elevated anti-DNA binding activities (de- 
fined for this purpose as > 40%), had elevated IFN 
titers ( P  < 0.005). The relationship of IFN titers and 
complement values is not statistically significant. 
When the serum complement was normal (C3 2 80 
mg/dl or  CH5O 2 104 units), 56.3% (18/32) of samples 
gave negative results for IFN, but 62.5% (25/40) of 
IFN titers were elevated when the complement was 
depressed (P > 0.10). 
Two specific case studies were chosen to illus- 
trate the fact that IFN titers relate most closely to the 
clinical manifestation of disease, often correlating bet- 
ter with disease activity than with the accepted sero- 
logic markers (anti-DNA binding and serum comple- 
ment). 
Patient JW had the highest IFN titer measured, 
and her course is depicted in Figure 2. She originally 
came to our clinic at age 44 with a 3-year history of 
SLE and an explosive flare of her disease 1 month 
after her prednisone dose had been rapidly tapered and 
discontinued. At that time, she had joint involvement, 
rash, pancytopenia, oral ulcers, weakness, fatigue, 
and anorexia. Proteinuria and hematuria were present, 
and focal membranous and proliferative glomerulone- 
phritis was shown by a renal biopsy. Results of 
serologic studies included a C3 of 27 mgldl and an anti- 
DNA binding activity of 93.6%. During the ensuing 
year she was treated with prednisone and hydroxy- 
chloroquine with gradual improvement of her symp- 
toms and serologic markers. During this period, her 
IFN titer dropped from 512 U/ml to less than 16 U/ml. 
Figure 3 depicts the course of NZ, a 17-year-old 
woman followed for approximately 2 years. When first 
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Figure 2. Clinical course and laboratory data of patient JW. 
seen, she was recovering from a flare of her disease 
manifested as polyserositis. She subsequently experi- 
enced further flares, with skin and renal changes, 
during which anti-DNA binding activity remained in 
the normal range while total hemolytic complement 
was depressed. Analysis of IFN titers in samples 
obtained during this period showed that the IFN levels 
rose, correlating with the clinical disease activity 
rather than with the anti-DNA binding levels. 
That the antiviral activity in the sera of the 
patients studied was due to IFN and not a nonspecific 
antiviral factor was confirmed by demonstrating spe- 
cies specificity by means of a lack of antiviral effect 
with mouse L cell monolayer targets. Furthermore, 
incubation of positive serum samples with VSV did 
not cause direct neutralization of the virus. 
In an attempt to characterize the IFN present, 
10 positive samples were treated with acid since IFN-a 
and IFN-P are stable at pH 2, but IFN-7 is labile (21). 
Only 1 of the samples analyzed in this fashion lost 
antiviral activity after dialysis at pH 2. This 1 sample 
had a low titer (16 U/ml), and examination of a sample 
with a higher titer from the same patient showed the 
IFN to be stable at pH 2. A sample of IFN-y produced 
by stimulation of normal human mononuclear cells 
with concanavalin A lost all antiviral activity (initial 
titer 128 U/ml) after acid dialysis. Further confirma- 
tion of the type of IFN present was made by demon- 
strating complete neutralization of the antiviral activi- 
ty of 4 of the positive samples by rabbit antibody to 
human IFN-a. Similar complete neutralization of a 
standard human lymphoblastoid IFN-a was also docu- 
mented. 
DISCUSSION 
The present study confirms the data previously 
reported by Hooks et al (21,22) and Osial et al (23), 
who documented the presence of IFN in the sera of 
patients with SLE. Detectable levels of IFN were 
found in the sera of 16 of 23 patients with SLE. When 
analyzed in regard to clinical disease activity, the data 
confirm the correlation between IFN levels and dis- 
ease activity: 75.6% of samples obtained when pa- 
tients had clinically active disease had positive test 
results, but only 9.1% of samples collected during 
Proleinuria biopsy - mixed nephropalhy 
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Figure 3. Clinical course and laboratory data of patient NZ. 
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periods of disease inactivity yielded positive results. 
This correlation is in agreement with the findings of 
Hooks et a1 (21,22). Contrary to previous reports, 
however, in this study the antiviral activity was shown 
to be stable at pH 2, and therefore more likely to be 
due to IFN-a rather than IFN-y. Neutralization of the 
antiviral activity by antibody to human IFN-a con- 
firmed that the IFN present was IFN-a. The concomi- 
tant presence of IFN-y in these samples at levels 
below those of the IFN-a cannot be entirely ruled out, 
however. Acid dialysis alone would fail to reduce IFN- 
a titers, so that any reduction in the lower levels of 
IFN-y present would not be apparent on the plaque 
reduction assay. The observation of complete neutral- 
ization of IFN activity by the antiserum to IFN-a 
strongly suggests that either no appreciable amount of 
IFN-y was present or that the antiserum has cross- 
reactivity with IFN- y. 
The data obtained in this report were also 
examined with respect to two generally accepted labo- 
ratory parameters of SLE disease activity, anti-DNA 
binding and complement levels. A significant relation- 
ship to anti-DNA binding activity was found; 69.7% of 
sera had elevated IFN levels when the anti-DNA 
binding was > 40%, but 57.1% gave negative results 
when the anti-DNA binding was < 20%. With respect 
to serum complement levels, no statistically significant 
relationship was found. Study of individual patients 
confirmed that the IFN titers correlated more closely 
with the clinical rather than the serologic manifesta- 
tions of disease activity. The relatively poor correla- 
tion of IFN titers with anti-DNA binding activity and 
complement levels is not necessarily an unexpected 
finding. The role of any individual serologic marker in 
the pathogenesis of the clinical disease activity of SLE 
is not well defined, and no serologic parameter has yet 
been found to correlate perfectly with disease activity 
(26). Each of the molecules measured as a serologic 
marker is produced independently and is probably 
removed at a different rate by different clearance 
mechanisms. Therefore, the time course of each mark- 
er during the disease process must be different, and 
independent serologic parameters would be expected 
to correlate better with disease activity rather than 
with each other. 
The finding of elevated IFN titers in the blood 
of patients with SLE, be it IFN-a or IFN-y, is of 
considerable interest. IFN is known to be intimately 
linked to the immune system; it is produced by both 
antigenic and mitogenic stimulation of lymphocytes as 
well as viral infection, and it is able to modulate a host 
of immune responses (2-4,6-20). The origin of the IFN 
in the blood of patients with SLE is unclear, but 
several possible etiologies exist: 1) Although there has 
been much investigation into the possible viral origin 
of SLE, little evidence to support a viral etiology 
exists to date, making it unlikely that the IFN measured 
in these patients results from viral stimulation. 2) The 
elevated IFN levels may result from the presence of 
circulating immune complexes. Immune complexes 
are known to be able to stimulate lymphocytes to 
secrete IFN (4). 3) Since antigenic stimulation of 
sensitized lymphocytes has been shown to be suffi- 
cient to cause production of IFN (4), serum IFN in 
patients with SLE may be a consequence of the same 
antigenic stimulation that results in the formation of 
autoantibodies. 4) Elevated IFN levels may be present 
as a homeostatic attempt to control immune function 
in patients with SLE. Patients with SLE are known to 
have diminished NK cell activity (27), and IFN has 
been shown to stimulate NK activity (14-17). Similar- 
ly, IFN can diminish antibody production in response 
to antigenic stimulation (7), and its presence may 
represent a homeostatic attempt to blunt autoantibody 
formation. 
The possibility that IFN itself might be respon- 
sible for some or all of the immune aberrations or may 
be a mediator of the clinical disease expression in SLE 
must be considered. These hypotheses are supported 
not only by the known immunomodulatory effects of 
IFN in humans, but also by observations made in the 
NZB and NZB/W murine systems. Several investiga- 
tors have employed IFN or IFN inducers in these mice 
in order to abrogate the naturally occurring autoim- 
mune disease activity (28-32). Contrary to what had 
been expected, however, in the majority of these 
studies, increased autoimmune disease activity and 
death occurred at an earlier age than usual, suggesting 
that IFN may play a direct role in mediating the 
pathophysiology of the autoimmune disease activity. 
At this time, measurement of serum IFN titers 
in patients with SLE provides another serologic mark- 
er of disease activity, but one that may not be any 
more specific than other currently available tests. 
However, much information remains to be discovered 
concerning the physiologic roles of IFN in the immune 
system. Because of the known immune aberrations in 
SLE, the finding of elevated levels of IFN in the sera 
of these patients is particularly important and requires 
further clarification to determine whether it plays a 
prominent role in the pathogenesis of the disease 
process or is merely an epiphenomenon. Further work 
will be necessary to 1 )  define the cellular origin of IFN 
in these patients and the stimulus that causes its 
formation, 2) document the effects of pharmacologic 
intervention on IFN levels and its correlation with 
406 
other immunologic variables in patients with SLE, and 
3) investigate the possibility of inhibiting or removing 
IFN to alter specific immune functions or the disease 
process. 
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